Fused bicyclic kinase inhibitors

A compound of Formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• X is selected from H, C1-3aliphatic, or —OC1-3aliphatic, either of which is optionally substituted with halo or —CN;
• W—V is C—N or N—C;
• Y1 and Y2 are independently N or CH, provided that not more than one of Y1 and Y2 is N;
• Y3 is NH or CH;
• Y4 is N or CH;
• Y5 is N or C, provided that not more than one of Y4 and Y5 is N;
• R1a, R1b, R1c, R1d, R1e are each independently selected from H, aliphatic, cyclic, —O-aliphatic, —O-cyclic, sulfide, sulfone, sulfoxide, amino, amido, carboxyl, acyl, ureido, or S-cyclic, any of the foregoing being optionally substituted, halo, or —CN;
• G1 is selected from H, aliphatic, or cyclic, either of which is optionally substituted;
• R17 and R18 are independently selected from H, aliphatic, —O-aliphatic, cyclic, amido, carboxyl, or amino, any of the foregoing being optionally substituted, —CN, or halo, provided that at least one of R17 and R18 is not H.